[go: up one dir, main page]

WO2008148572A1 - Combinaisons de principes actifs anti-inflammatoires pour le traitement de maladies de la peau et des muqueuses - Google Patents

Combinaisons de principes actifs anti-inflammatoires pour le traitement de maladies de la peau et des muqueuses Download PDF

Info

Publication number
WO2008148572A1
WO2008148572A1 PCT/EP2008/004566 EP2008004566W WO2008148572A1 WO 2008148572 A1 WO2008148572 A1 WO 2008148572A1 EP 2008004566 W EP2008004566 W EP 2008004566W WO 2008148572 A1 WO2008148572 A1 WO 2008148572A1
Authority
WO
WIPO (PCT)
Prior art keywords
allergic
group
combination according
skin
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/004566
Other languages
German (de)
English (en)
Inventor
Marianne Petersen-Braun
Sabine Rabini
Sabine GLÄSER
Klaus Kluthe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Consumer Care AG
Original Assignee
Bayer Consumer Care AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Consumer Care AG filed Critical Bayer Consumer Care AG
Priority to DE112008001135T priority Critical patent/DE112008001135A5/de
Publication of WO2008148572A1 publication Critical patent/WO2008148572A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines

Definitions

  • the invention relates to combinations comprising at least one anti-inflammatory agent and at least one antiallergic agent and / or at least one selected from the pantothenic acid and pantothenic acid group selected active ingredient for the treatment of diseases and disease symptoms of the skin and mucous membranes, in particular allergic diseases and symptoms, drugs containing them and its production.
  • the available for an anti-allergic therapy drugs are generally symptomatic, since a causal therapy could be effected only by complete antigenic deficiency.
  • a causal therapy could be effected only by complete antigenic deficiency.
  • drugs from the drug class of antihistamines and from the class of corticosteroids are used.
  • mediators eg histamine
  • mast cells and basophilic granulocytes plays a central role.
  • mediators eg histamine
  • the released mediators cause increased permeability of vessels, spastic contractions of the smooth muscle, and - by activation of other cell types of the immune system - local inflammatory reactions.
  • Antihistamines prevent the occurrence or effects of mediators of allergic reactions (prostaglandins, especially PGD2, and histamine) and have an antagonistic effect on the migration of eosinophilic granulocytes in atopic patients.
  • the allergic reaction can be counteracted by administration of anti-inflammatory and immunosuppressive corticosteroids (glucocorticoids). Based on this, the use of these drug classes in the symptomatic therapy of allergic diseases.
  • the symptoms caused by allergic reactions mainly affect the skin, the mucous membranes, especially the mucous membranes of the respiratory tract (nasal cavity, paranasal sinuses, oral cavity, pharynx, larynx, trachea, bronchi, bronchioles), the bronchi, the gastrointestinal tract, the conjunctiva of the eye as well as the vascular system.
  • Antihistamines and glucocorticoids are approved as both oral (i.e., systemic) and topical drugs for the treatment of allergic symptoms.
  • the therapeutic efficacy of the known antihistamines and glucocorticoids is often inadequate and an increase in dosage is not justifiable due to the associated risk of side effects. Often it comes with the symptomatic anti-allergic therapy
  • agents from the class of mast cell degranulation inhibitors and from the class of leukotriene receptor antagonists are used. Furthermore, it is known from WO 01/19330 A1 that inhibition of the release of mediators from mast cells is effected by pantothenic acid and its derivatives (eg dexpanthenol), but also by the amino acid glycine, and thereby the allergic reaction can be alleviated.
  • dexpanthenol is used as a component in topical medicines.
  • EP 1 159958 A1 describes a nasal ointment containing dexpanthenol as a nourishing ingredient.
  • DE 10005936 A1 discloses a cream for external use in the nose area, which contains a combination of allantoin and dexpanthenol.
  • DE 19541919 A1 describes a pharmaceutical preparation for the treatment of acute rhinitis which comprises a sympathomimetic with 2-imidazoline structure (eg oxymetazoline) suitable for topical use in combination with a pantothenol derivative, e.g. As dexpanthenol contains.
  • the combination with dexpanthenol alleviated the side effects caused by the sympathomimetic.
  • the object underlying the present invention was to provide medicaments for the therapeutic treatment of diseases and disease symptoms of the skin and mucous membranes, in particular of allergic diseases and symptoms of the skin or the mucous membranes, which have improved efficacy and / or a lower side-effect potential.
  • this object is achieved by a combination comprising at least one antiinflammatory active ingredient and additionally at least one antiallergic active ingredient or / and at least one of the pantothenic acid and pantothenic acid derivatives
  • a combination comprising at least one antiinflammatory active ingredient and additionally at least one antiallergic active ingredient or / and at least one of the pantothenic acid and pantothenic acid derivatives
  • the inventive Combinations are useful m for the treatment of allergic symptoms or diseases of the skin, mucous membranes, especially the respiratory tract and especially the nose, or the conjunctiva.
  • the active compound combinations according to the invention are also suitable for the treatment of other dermatological diseases, in particular for the treatment of inflammatory skin diseases
  • inventive combinations are also advantageous because they have a reduced side effect potential
  • the occurrence of side effects such as skin dryness can be significantly reduced by means of the inventive drugs due to the use of said drug combinations This is particularly important because some antiallergic agents themselves in topical application
  • Additional advantages result with the medicaments according to invention in that due to the content of antiinflammato ⁇ schen active substances or to Pantothensaure or Pantothensaured ⁇ vaten a favorable influencing of the Entzundungssymptome, like redness, swelling and heat development, Dry or burning mucous membranes, or crusting allows
  • the term “antnnflammato ⁇ sch” is considered to be synonymous with the term “antiphlogistic”
  • the term “substance or” active ingredient refers both to individual, chemically defined compounds as well as mixtures, natural products or natural product mixtures
  • the active ingredient combination comprises at least one anti-inflammatory agent selected from the group consisting of sulphonated shale oils, bituminosulphonates, in particular ammonium bituminosulphonate or bituminous sulphonate, as well as coal tar, coal tar extracts and other tars.
  • the active ingredients of the abovementioned group are preferably used in medicaments for external application on the skin.
  • the above-mentioned substances are preferably used in a proportion of 0.1 to 70 wt .-%, in particular from 5 to 50 wt .-%, in each case based on the respective drug.
  • the active ingredient combination comprises at least one anti-inflammatory substance which is of vegetable origin.
  • This may be a single substance, a mixture of substances, a liquid or solid or dry extract, a distillate or an oil.
  • herbal substances which are borage (Borago officinalis), evening primrose (Oenothera biennis), witch hazel, common sunflower (Echinacea angustifolia), chamomile (Chamomilla recucita, C. nobile, Matricaria matricarioides), arnica (Arnica chamissonis, A. montana).
  • Calendula Calendula officinalis
  • thyme Thymus spp.
  • Aloe vera sage
  • mint Meatha spp.
  • St. John's wort Hypericum perforatum
  • rosemary Rosmarinus officinalis
  • sea-buckthorn Hippophae rhamnoides
  • Cardiospermum halicacabum Myrrh (Commiphora spp.), Ratanhia, Fennel (Foeniculum vulgare), Willow (Salix spp.), Yarrow (Achillea millefolium), Coltsfoot (Tussilago farfara), Comfrey (Symphytum officinale), Devil's Claw (Harpagophytum procumbens), Bittersweet (Solanum dulcamara), Elderberry (Sambucus nigra), Eucalyptus, Tea tree (Melale
  • herbal substances with anti-inflammatory effect are in particular tannins, essential oils, Azulene, Proazulene, bisabolols, bisabololides, flavonoids, flavones, anthocyanins, triterpenes, monoterpene alcohols, phenolcarboxylic acids, polyphenols, unsaturated fatty acids, hypericin, carotenoids, allantoin, bromelain, glycyrrhizin, glycyrrhizic acid or Salts of Glycyrrhizinkla, as well as combinations of the aforementioned substances into consideration.
  • tannins or tannin extracts of plant origin and synthetic tanning agents can be used, for.
  • herbal substances with anti-inflammatory effect in particular evening primrose oil and borage oil and other vegetable oils with anti-inflammatory effect, such as. As wheat germ oil, into consideration.
  • the proportion of plant anti-inflammatory substances is preferably 0.05 to 75% by weight, preferably 0.1 to 50% by weight, depending on the nature of the active ingredients, the particular dosage form used and the nature of the therapeutic use to the respective drug.
  • the combination according to the invention comprises at least one anti-inflammatory active ingredient selected from the group consisting of vitamin A, carotenes, carotenoids, tretinoin (all-trans-retinoic acid), tocopherols (vitamin E) and biotin.
  • active ingredients are preferably used in a proportion of 0.01 to 20 wt .-%, in particular from 0.05 to 5 wt .-%, based on the respective drug.
  • the invention includes both active ingredient combinations containing only a single anti-inflammatory drug from said drug groups, as well as drug combinations containing two or more anti-inflammatory drugs, each selected from one or more of the aforementioned groups.
  • pantothenic acid derivatives includes in particular dexpanthenol, DL-panthenol, salts of pantothenic acid (eg Na-pantothenate, Ca-pantothenate), esters of pantothenic acid (eg ethyl, methyl ester), panthenol-ether (e.g. Ethyl or methyl ether), panthenol thioether and panthenyl triacetate.
  • the relative proportion of dexpanthenol (or of the pantothenic acid derivative and / or pantothenic acid) can be varied within wide limits, depending on the respective desired effects.
  • the dexpanthenol content is 0.1 to 95 wt .-%, in particular 0.5 to 50 wt .-%, particularly preferably 0.5 to 30 wt .-%, each based on the total amount of active ingredient.
  • antiallergic agents are active substances selected from the group consisting of antihistamines, corticosteroids, synthetic mast cell degranulation inhibitors and leukotriene receptor antagonists.
  • drugs from the drug class of antihistamines and from the drug class of corticosteroids used.
  • the corticosteroids used according to the invention are generally glucocorticoids.
  • Antihistamines histamine HI receptor antagonists, histamine H2 receptor antagonists
  • which are suitable for a therapeutic treatment of allergic symptoms of the skin or mucous membranes and are therefore suitable for use in the combination of active substances according to the invention are known in principle to the person skilled in the art.
  • Antihistamines are substances that antagonize the action of the released histamine on the Hl receptor (or the H2 receptor), thereby eliminating the effect of histamine on Hl receptors, especially on the peripheral vessels.
  • Particularly suitable antihistamines in connection with the present invention are the following active substances: ketotifen, thonzylamine, mepyramine, thenalidine, triphenylamine, chloropyramine, promethazine, tolpropamine, dimetindene, clemastine, bamipine, loratadine, isothipendyl, diphenhydramine, diphenhydramine methyl bromide, chlorphenoxamine, pheniramine, Diphenylpyraline, dioxopromethazine, dimenhydrinate, thiethylperazine and meclocine, azelastine, levocabastine, astemizole, mebhydroline, terfenadine, mequitazine, cetirizine,
  • the relative proportion of the antihistamine is determined in a manner known to those skilled in the art, depending on the pharmacological properties and the nature of the particular dosage form used.
  • corticosteroids are basically all glucocorticoid drugs into consideration, whose therapeutic efficacy in the treatment of allergic diseases or symptoms is known.
  • the following active ingredients are contemplated: triamcinolone, dexamethasone, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone buteprate, prednisolone, betamethasone, methylprednisolone, clobetasone, flumetasone, fluocortin, fluperolone, fluorometholone, flupredniden, desonide, triamcinolone, alclometasone , dexamethasone, clocortolone, betamethasone, Fluclorolon, desoximetasone, fluocinolone, fluocortolone, diflucortolone, fludroxycortide, fluocinonide, budesonide,
  • the invention further includes embodiments which provide that the drug combination comprises at least one synthetic antiallergic drug not selected from the group consisting of antihistamines and corticosteroids.
  • the drug combination comprises at least one synthetic antiallergic drug not selected from the group consisting of antihistamines and corticosteroids.
  • Mast cell degranulation inhibitors also referred to as mast cell stabilizers, are substances that inhibit the release of histamine from mast cells.
  • exemplary and preferred representatives of this class of drugs are cromoglycic acid, spaglumic acid, nedocromil and lodoxamide.
  • Leukotriene receptor antagonists are substances that inhibit leukotriene synthesis and / or leukotriene effects. Leukotrienes are involved in the development and chronicity of allergic inflammatory symptoms. Exemplary and preferred representatives of this class of drugs are montelukast, pranlukast, ibudilast and zafirlukast.
  • the invention encompasses both active ingredient combinations containing only a single antiallergic active ingredient - selected from one of the abovementioned groups - as well as active ingredient combinations which contain two or more antiallergic active ingredients, each selected from one or more of the abovementioned groups.
  • the proportion of the antiallergic agent is preferably in the range from 0.01 to 25% by weight, in particular from 0.05 to 10% by weight, based in each case on the total amount of active ingredient.
  • active ingredients exemplified in the preceding paragraphs are not a complete and exhaustive list of active ingredients from the classes of herbal anti-inflammatory drugs, antihistamines, glucocorticoids, synthetic mast cell degranulation inhibitors and leukotriene receptor antagonists.
  • the mention of these substances is only illustrative of these drug classes.
  • other active ingredients from the mentioned classes of active substances can be used in the context of the invention.
  • the active substances according to the invention can also be used in the form of their pharmaceutically acceptable salts.
  • Pharmaceutically acceptable salts of the compounds of the invention may be acid addition salts of the compounds with mineral acids, carboxylic acids or sulfonic acids. Particular preference is given, for example, to salts with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid, oxalic acid, succinic acid, butyric acid, decanoic acid, aspartic acid or benzoic acid. - o -
  • salts with customary bases can also be mentioned as salts, for example alkali metal salts (for example sodium or potassium salts), alkaline earth salts (for example calcium or magnesium salts) or ammonium salts derived from ammonia or organic amines such as, for example, diethylamine, triethylamine, ethyldiisopropylamine, procaine, Dibenzylamine, N-methylmorpholine, dihydroabiethylamine, 1 -phenamine or methyl-piperidine.
  • alkali metal salts for example sodium or potassium salts
  • alkaline earth salts for example calcium or magnesium salts
  • ammonium salts derived from ammonia or organic amines such as, for example, diethylamine, triethylamine, ethyldiisopropylamine, procaine, Dibenzylamine, N-methylmorpholine, dihydroabiethylamine, 1 -phenamine or methyl-pipe
  • the active substance combination according to the invention preferably comprises a) at least one anti-inflammatory substance selected from the group consisting of sulphonated shale oils, bituminous sulphonates, coal tar extracts and other tars, and at least one antiallergic active substance, or b) at least one herbal substance having an antiinflammatory effect and at least one or (c) at least one anti-inflammatory agent selected from the group consisting of sulfonated shale oils, bituminosulfonates, coal tar, coal tar extracts and other tars, at least one anti-inflammatory agent, and at least one antiallergic agent, or d) at least one anti-inflammatory agent A fabric selected from the group consisting of sulfonated shale oils, bituminous sulfonates, coal tar, coal tar extracts and other tars, and at least one of the Pan or e) at least one herbal substance having an antiinflammatory effect and at least one active substance selected from the pantothenic acid and pan
  • an active ingredient combination (a) to (h) consists exclusively of the active ingredient components listed above.
  • those described above Active ingredient combinations contain at least one other active ingredient, which is not selected from the above-mentioned active ingredient groups.
  • Said further active ingredient may preferably be selected from the group comprising dermatics (eg urea, heparin, hyaluronic acid, glycine, lactic acid and its salts, pyroglutamic acid, salicylic acid, dimethyl fumarate and ethyl hydrogen fumarate), antibiotics (eg sulphonamides, erythromycin ), Antiseptics (eg chlorhexidine), local anesthetics (eg lidocaine, polidocanol), decongestants (eg sympathomimetics such as xylometazoline) as well as skin care substances (eg jojoba oil, lanolin, vegetable oils and fats ) and sunscreen substances (UV-A filter, UV-B filter
  • the proportion of the said further active ingredient (s) can be chosen freely, this proportion is preferably 0.05 to 50 wt .-%, in particular 0.1 to 20 wt .-%, each based on the drug.
  • the active ingredient combination additionally contains glycine.
  • the additional administration of glycine can achieve a further increase in therapeutic efficacy.
  • glycine is present in a proportion of 0.1 to 25 wt .-%, in particular 0.5 to 10 wt .-%, in each case based on the total active ingredient content, in the active ingredient combination.
  • Combination within the meaning of the invention is understood to mean not only administration forms which contain all components in a common administration form (so-called fixed combinations), and combination packages which contain the components separated from one another in a single package ("kit”) but also simultaneously or staggered components, if used to treat the same disease / symptom.
  • the active substances of the medicaments and pharmaceutical formulations according to the invention are particularly suitable for being formulated in a fixed combination. It is known that the application reliability (compliance) in patients depends crucially on the factors number of dosage forms per application time, and optionally on the size and weight of the (solid peroral) dosage form. Therefore, both the number of different medicines to be taken separately should be as small as possible (the advantage of a fixed combination) and, if necessary, the size and weight of a solid oral dosage form should be kept as small as possible without compromising therapeutic potency. This makes the application as comfortable as possible for the patient. By implementing fixed combinations, the highest possible patient compliance is provided and the safety and reliability of the therapy are decisively improved.
  • the medicaments according to the invention preferably contain the active ingredient combination according to the invention in the form of a "fixed combination"; This means that all active ingredients which form the respective active ingredient combination are present together in a dosage form and administered together.
  • the active compound combinations according to the invention in the form of medicaments are generally administered locally (i.e., topically) to those areas of the skin or mucous membrane which are affected by allergic symptoms.
  • the medicaments according to the invention are preferably formulated as solid, semi-solid, liquid or gaseous dosage forms for topical application to the skin or mucous membrane, in particular as powder, powder, plaster, dust aerosol, granules, lozenge, lozenge, chewing gum, gel, ointment, lotion, paste, Shampoo, emulsion, suspension, solution, gargle, juice, syrup, oil, aerosol or inhalant.
  • the following dosage forms are particularly suitable: eye ointments, eye sprays, eye tablets, eye drops, eye lotions, eye baths, eye salves.
  • the following dosage forms are considered: nose drops, nasal sprays, nose creams, creams, lozenges, suspensions or solutions, tinctures, lotions, emulsions, nose powder, powders, gels, nasal douche, nasal irrigation, aerosols, inhalants.
  • the invention also includes dosage forms for the external treatment of the nose (eg, ointments, gels, creams).
  • the following dosage forms are particularly suitable: aerosol, inhalant (suspensions, solutions), throat spray, oral spray, powder for inhalation, drops, tablets, lozenges, Pastilles, capsules, syrups, tinctures, gargles.
  • dosage forms for the treatment of allergic symptoms of the skin or mucous membranes, especially the following dosage forms are considered: gels, ointments, solutions, powders, creams, sprays, emulsions, suspensions, tinctures, lotions.
  • the abovementioned solid, semisolid, liquid or gaseous dosage forms are known in principle to the person skilled in the art and are described in the literature; the same applies with regard to the preparation of such dosage forms and the pharmaceutically acceptable auxiliaries suitable therefor.
  • the preparation of the medicaments according to the invention can take place taking into account the active compound combinations to be used according to the invention with the methods known for the respective dosage form using pharmaceutical excipients, as are familiar to the person skilled in the art.
  • Suitable adjuvants are, for example: particulate carriers (eg talc, zinc oxide, starch, starch derivatives, diatomaceous earth); gel-forming substances (eg gelatin, tragacanth, cellulose derivatives, alginates, polyacrylic acid); Humectants (eg, urea, glycerol, propylene glycol), pressure-sensitive adhesives (eg, polyacrylates, as well as tackifier resins); Ointment bases (eg vaseline, fats, cellulose derivatives, polyacrylic acid, polyethylene glycols); Emulsifiers (eg wool wax, sorbitan esters, monoglycerides); Preservatives (e.g., benzalkonium chloride), antioxidants (e.g., butylhydroxyanisole), thickening agents (e.g., hydroxypropylmethylcellulose), pH corrigents; Binders (eg polyvinylpyrrolidone, starch, hydroxypropylmethylcellulose
  • Liquid dosage forms are also prepared by standard methods with pharmaceutically acceptable excipients and either contain the active ingredients dissolved or suspended. Typical application volumes of these pharmaceutical preparations are between 1 and 10 ml.
  • auxiliaries in these liquid formulations are: solvents (eg water, alcohol, natural and synthetic oils such as medium-chain triglycerides), solubilizers (eg glycerol, glycol derivatives), wetting agents (eg polysorbate, sodium lauryl sulfate ), as well as other auxiliaries, which are needed for the preparation of pharmaceutical formulations of the desired properties, eg viscosifiers, pH corrigents, sweeteners and flavors, antioxidants, stabilizers and / or preservatives.
  • solvents eg water, alcohol, natural and synthetic oils such as medium-chain triglycerides
  • solubilizers eg glycerol, glycol derivatives
  • wetting agents eg polysorbate, sodium lauryl sulfate
  • dosage forms may be used which enable a delayed or controlled release of active ingredient.
  • Drug forms with controlled or prolonged release of active ingredient eg depot preparations and sustained-release preparations, as well as therapeutic systems
  • active ingredient eg depot preparations and sustained-release preparations, as well as therapeutic systems
  • composition of the drugs by known means, for example by means of coatings, embedding or microencapsulation, drug release from the drug can be controlled.
  • the delayed or controlled release may optionally affect only one, several or all active ingredient components of the fixed drug combination.
  • the total active ingredient content in the medicaments according to the invention is preferably in the range from 0.05 to 70% by weight, in particular in the range from 0.1 to 50% by weight, particularly preferably in the range from 0.5 to 15% by weight. , in each case based on the total weight of a drug.
  • the active substances can be present in the medicaments in particular in particulate, dispersed, dissolved, suspended or emulsified form.
  • the medicaments according to the invention are preferably medicaments for intranasal, intraocular or dermal application, or medicaments for inhalation administration for the treatment of the respiratory tract (in particular the bronchi), or medicaments for local application in the oral and / or pharyngeal area.
  • the medicaments according to the invention are particularly suitable for the treatment of allergic symptoms of the nasal mucosa, the conjunctiva, the skin, the oral mucosa, the mucosa of the pharynx, or the lower respiratory tract (eg trachea, bronchi, bronchioles).
  • the invention further extends to the use of a combination of active substances as defined above for the treatment of diseases and disease symptoms of the skin, mucosa (especially mucous membranes of the respiratory tract) or conjunctiva, as well as to the use of such an active ingredient combination for the manufacture of a medicament for the treatment of said allergic symptoms.
  • treatment includes preventive (prophylactic) treatment.
  • allergic symptoms are, in particular, those occurring in the following allergic diseases: atopic eczema, psoriasis, contact dermatitis, Allergic rhinitis, allergic rhinoconjunctivitis, allergic conjunctivitis, allergic sinusitis Insect bites, drug allergy, drug eruption.
  • the aforementioned allergic symptoms include in particular the following: itching; Redness;
  • Hyperaemia, edema, hypertrophy or swelling of a mucous membrane especially the
  • nasal mucous membrane increased secretion of secretions (serous, mucous) of a mucous membrane, especially the nasal mucosa; Sneezing, sneezing attacks; Obstruction of nasal breathing; Redness and swelling of the conjunctiva of the eye, growths of the conjunctiva; Eyelid edema, lids.
  • the active ingredient combinations and medicaments according to the invention can be used for the treatment of diseases of the skin and the subcutaneous tissue, in particular for the treatment of the following skin diseases: infections of the skin or subcutis caused by bacteria, fungi or viruses, in particular impetigo, abscesses, boils, Carbuncle; bullous dermatoses, in particular pemphigoid diseases; non-allergic dermatitis; loan; pruritus; decubitus; lupus; Leg Ulcer.
  • the invention further includes a method for the therapeutic treatment of a person suffering from a disease of the skin or the subcutaneous tissue, or the one or more allergic
  • Such a therapeutic method of the invention comprises administering a fixed one
  • Active substance combination in a therapeutically effective dose. If necessary, the administration of the drug combination is repeated at appropriate intervals to achieve the desired therapeutic effect.
  • the administration of the drug combination is preferably carried out by means of a solid, semi-solid, liquid or gaseous dosage form, as mentioned above.
  • the active ingredient combination, or a drug containing such a combination is generally applied topically, ie to those areas of the skin or mucous membrane affected by allergic symptoms.
  • the drug or drug combination is applied to the skin, to a mucous membrane, orally, intranasally, intratracheally, intrabronchially or intraocularly.
  • the particular suitable therapeutic dose depends on the nature of the active ingredients contained in the respective drug combination and the nature of the symptoms to be treated, and can be determined in a manner known to those skilled in the art.
  • the medicaments according to the invention may contain the active substances mentioned in the usual dosages. Due to the mentioned synergistic effect, the dosage of each active ingredient of the active ingredient combination contained in the medicaments according to the invention can be chosen lower than the dosage which is customary for a single preparation of the respective active ingredient.
  • the active compound combinations and medicaments according to the invention can be used not only in the field of human medicine but also in the field of veterinary medicine for the treatment of allergic symptoms of the skin or mucous membrane.
  • an ointment base white vaseline, wool wax, medium-chain triglycerides.
  • the ointment can be used for the treatment of eczema, especially allergic eczema, as well as for
  • Treatment of psoriasis vulgaris be used.
  • the ointment is applied thinly one to three times daily to the affected skin.
  • an ointment base white vaseline, castor oil, propylene glycol.
  • the ointment can be used to treat eczema, especially allergic eczema.
  • the ointment is applied thinly one to three times daily to the affected skin.
  • hydrogel glycol, hydroxypropylcellulose, isopropanol, propylene glycol.
  • the hydrogel is used to treat itchy skin diseases, especially allergic skin diseases.
  • the gel is applied thinly several times daily to the affected skin.
  • a lipophilic cream white vaseline, wool wax, wool wax alcohols, sorbitan fatty acid esters, purified water.
  • the cream is used to treat eczema, dermatitis and inflammatory dermatoses.
  • the cream is applied one to several times a day thinly on the affected skin.
  • ointment base wool wax, wool wax alcohols, medium chain triglycerides, white vaseline, purified water.
  • the ointment is used to treat skin and mucous membrane inflammation.
  • ointment base wool wax, wool wax alcohols, medium chain triglycerides, white vaseline, purified water.
  • the ointment is used to treat inflammatory skin diseases.
  • Example 7 Ointment 2 wt .-% chamomile extract l, 5 wt .-% chlorophenoxamine-HCl 5 wt .-% dexpanthenol
  • ointment base wool wax, wool wax alcohols, medium chain triglycerides, white vaseline, propylene glycol, purified water.
  • the ointment is used to treat allergic and / or inflammatory skin diseases.
  • Excipients purified water, benzalkonium chloride, disodium EDTA.
  • the spray volume is 0.14 ml, corresponding to a single dose of 0.14 mg azelastine HCl per spray.
  • the nasal spray is used to treat allergic rhinitis.
  • one spray is injected into each nostril one to three times a day.
  • Excipients purified water, benzalkonium chloride, disodium EDTA.
  • the spray volume is 0.14 ml, corresponding to a single dose of 0.14 mg azelastine HCl per spray.
  • the nasal spray is used to treat allergic rhinitis and other inflammatory diseases of the nasal mucosa and paranasal sinuses. For application one to several times a day a spray is sprayed into each nostril.
  • the spray volume is 0.09 ml, corresponding to a single dose of 2.8 mg
  • Cromolynic acid per spray is Cromolynic acid per spray.
  • the nasal spray is used to treat allergic rhinitis.
  • one spray is injected into each nostril one to five times a day.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des combinaisons comprenant au moins un principe actif anti-inflammatoire et au moins un principe actif anti-allergique et/ou un acide pantothénique et/ou des dérivés d'acide panthothénique du groupe du principe actif sélectionné pour traiter les maladies et les symptomes des maladies de la peau et des muqueuses, en particulier des maladies et des symptomes allergiques, des médicaments les renfermant et leur procédé de fabrication.
PCT/EP2008/004566 2007-06-08 2008-06-07 Combinaisons de principes actifs anti-inflammatoires pour le traitement de maladies de la peau et des muqueuses Ceased WO2008148572A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE112008001135T DE112008001135A5 (de) 2007-06-08 2008-06-07 Antiinflammatorische Wirkstoffkombinationen zur Behandlung von Erkrankungen der Haut und Schleimhäute

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07011304 2007-06-08
EP07011304.8 2007-06-08

Publications (1)

Publication Number Publication Date
WO2008148572A1 true WO2008148572A1 (fr) 2008-12-11

Family

ID=39760024

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/004566 Ceased WO2008148572A1 (fr) 2007-06-08 2008-06-07 Combinaisons de principes actifs anti-inflammatoires pour le traitement de maladies de la peau et des muqueuses

Country Status (2)

Country Link
DE (1) DE112008001135A5 (fr)
WO (1) WO2008148572A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579655A (zh) * 2012-03-27 2012-07-18 李文汉 治疗口腔溃疡的中药外敷制剂
CN103520512A (zh) * 2013-11-01 2014-01-22 山东省千佛山医院 一种治疗面赤型背痈的中药洗剂制备方法
CN103520563A (zh) * 2013-11-01 2014-01-22 姚晓红 一种治疗嗜食猪大肠型背痈的中药洗剂制备方法
CN103536714A (zh) * 2013-11-01 2014-01-29 董翠兰 一种治疗下焦湿热型背痈的中药洗剂制备方法
CN103536799A (zh) * 2013-11-01 2014-01-29 康平 一种治疗肝胃郁热型背痈的中药洗剂制备方法
CN103550568A (zh) * 2013-11-01 2014-02-05 李静 一种治疗过食高热食品型背痈的中药洗剂制备方法
CN103550577A (zh) * 2013-11-01 2014-02-05 卢现霞 一种治疗嗜食胡椒型背痈的中药洗剂制备方法
CN103550571A (zh) * 2013-11-01 2014-02-05 赵涛 一种治疗嗜食大蒜型背痈的中药洗剂制备方法
WO2018015593A1 (fr) * 2016-07-07 2018-01-25 Diater Laboratorio De Diagnóstico Y Aplicaciones Terapéuticas, S.A. Compositions d'acide cromoglicique pour le traitement de la dermatite
CN111317719A (zh) * 2018-12-13 2020-06-23 复旦大学 具有抗病毒活性的一支蒿鼻用喷雾剂
WO2022261723A1 (fr) * 2021-06-17 2022-12-22 Pant Harshita Compositions et leurs utilisations
PL442889A1 (pl) * 2022-11-21 2024-05-27 Uniwersytet Rolniczy im. Hugona Kołłątaja w Krakowie Sposób obniżania właściwości alergizujących białek pszenicy ozimej
DE102023135949A1 (de) 2023-12-20 2025-06-26 Joachim Häfele Wirkstoffkombination

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2841527A (en) * 1955-11-07 1958-07-01 Us Vitamin Corp Medicinal emulsions
US3066072A (en) * 1957-06-27 1962-11-27 Biorex Laboratories Ltd Extract from liquorice root having anti-inflammatory activities
US4512978A (en) * 1980-01-24 1985-04-23 Inwood Louis R Dermatological composition useful in the treatment of psoriasis
US4908213A (en) * 1989-02-21 1990-03-13 Schering Corporation Transdermal delivery of nicotine
EP0719149A1 (fr) * 1993-09-14 1996-07-03 Pierre Fabre Dermo-Cosmetique Composition dermocosmetique antifongique
US5633284A (en) * 1992-06-08 1997-05-27 Pitmy International N.V. Nitrous oxide containing dermatological composition
WO2000002521A2 (fr) * 1998-07-10 2000-01-20 Vit-Immune, L.C. Soulagement des symptomes de reactions allergiques
WO2000051605A1 (fr) * 1999-03-01 2000-09-08 Schering Corporation Compositions et procedes pour traiter la dermatite atopique, l'angio-oedeme et autres troubles, en utilisant des antihistamines et des glucocorticoides
US6309656B1 (en) * 1998-11-27 2001-10-30 Peter T. Pugliese Cosmetic and skin protective compositions
US6387382B1 (en) * 1998-11-23 2002-05-14 Axiom Laboratories, Inc. Water-proof, respirable, skin barrier composition
WO2004009038A2 (fr) * 2002-07-18 2004-01-29 Cognis Deutschland Gmbh & Co. Kg Preparations cosmetiques a proprietes antibacteriennes
US6708822B1 (en) * 1999-11-30 2004-03-23 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
WO2006099591A1 (fr) * 2005-03-16 2006-09-21 Elan Pharma International Limited Formulations nanoparticulaires d'un antagoniste du recepteur de leukotriene/d'un corticosteroide

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2841527A (en) * 1955-11-07 1958-07-01 Us Vitamin Corp Medicinal emulsions
US3066072A (en) * 1957-06-27 1962-11-27 Biorex Laboratories Ltd Extract from liquorice root having anti-inflammatory activities
US4512978A (en) * 1980-01-24 1985-04-23 Inwood Louis R Dermatological composition useful in the treatment of psoriasis
US4908213A (en) * 1989-02-21 1990-03-13 Schering Corporation Transdermal delivery of nicotine
US5633284A (en) * 1992-06-08 1997-05-27 Pitmy International N.V. Nitrous oxide containing dermatological composition
EP0719149A1 (fr) * 1993-09-14 1996-07-03 Pierre Fabre Dermo-Cosmetique Composition dermocosmetique antifongique
WO2000002521A2 (fr) * 1998-07-10 2000-01-20 Vit-Immune, L.C. Soulagement des symptomes de reactions allergiques
US6387382B1 (en) * 1998-11-23 2002-05-14 Axiom Laboratories, Inc. Water-proof, respirable, skin barrier composition
US6309656B1 (en) * 1998-11-27 2001-10-30 Peter T. Pugliese Cosmetic and skin protective compositions
WO2000051605A1 (fr) * 1999-03-01 2000-09-08 Schering Corporation Compositions et procedes pour traiter la dermatite atopique, l'angio-oedeme et autres troubles, en utilisant des antihistamines et des glucocorticoides
US6708822B1 (en) * 1999-11-30 2004-03-23 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
WO2004009038A2 (fr) * 2002-07-18 2004-01-29 Cognis Deutschland Gmbh & Co. Kg Preparations cosmetiques a proprietes antibacteriennes
WO2006099591A1 (fr) * 2005-03-16 2006-09-21 Elan Pharma International Limited Formulations nanoparticulaires d'un antagoniste du recepteur de leukotriene/d'un corticosteroide

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579655A (zh) * 2012-03-27 2012-07-18 李文汉 治疗口腔溃疡的中药外敷制剂
CN103520512A (zh) * 2013-11-01 2014-01-22 山东省千佛山医院 一种治疗面赤型背痈的中药洗剂制备方法
CN103520563A (zh) * 2013-11-01 2014-01-22 姚晓红 一种治疗嗜食猪大肠型背痈的中药洗剂制备方法
CN103536714A (zh) * 2013-11-01 2014-01-29 董翠兰 一种治疗下焦湿热型背痈的中药洗剂制备方法
CN103536799A (zh) * 2013-11-01 2014-01-29 康平 一种治疗肝胃郁热型背痈的中药洗剂制备方法
CN103550568A (zh) * 2013-11-01 2014-02-05 李静 一种治疗过食高热食品型背痈的中药洗剂制备方法
CN103550577A (zh) * 2013-11-01 2014-02-05 卢现霞 一种治疗嗜食胡椒型背痈的中药洗剂制备方法
CN103550571A (zh) * 2013-11-01 2014-02-05 赵涛 一种治疗嗜食大蒜型背痈的中药洗剂制备方法
WO2018015593A1 (fr) * 2016-07-07 2018-01-25 Diater Laboratorio De Diagnóstico Y Aplicaciones Terapéuticas, S.A. Compositions d'acide cromoglicique pour le traitement de la dermatite
CN109715153A (zh) * 2016-07-07 2019-05-03 迪亚特实验室诊断和治疗应用公司 用于治疗皮炎的包含色甘酸的组合物
RU2754006C2 (ru) * 2016-07-07 2021-08-25 Нутра Эссеншиал Отк, С.Л. Композиции, содержащие кромоглициевую кислоту, для лечения дерматита
CN111317719A (zh) * 2018-12-13 2020-06-23 复旦大学 具有抗病毒活性的一支蒿鼻用喷雾剂
WO2022261723A1 (fr) * 2021-06-17 2022-12-22 Pant Harshita Compositions et leurs utilisations
PL442889A1 (pl) * 2022-11-21 2024-05-27 Uniwersytet Rolniczy im. Hugona Kołłątaja w Krakowie Sposób obniżania właściwości alergizujących białek pszenicy ozimej
PL246708B1 (pl) * 2022-11-21 2025-02-24 Uniwersytet Rolniczy im. Hugona Kołłątaja w Krakowie Sposób obniżania właściwości alergizujących białek pszenicy ozimej
DE102023135949A1 (de) 2023-12-20 2025-06-26 Joachim Häfele Wirkstoffkombination

Also Published As

Publication number Publication date
DE112008001135A5 (de) 2010-04-15

Similar Documents

Publication Publication Date Title
WO2008148572A1 (fr) Combinaisons de principes actifs anti-inflammatoires pour le traitement de maladies de la peau et des muqueuses
EP2214658B1 (fr) Préparation contenant des osmolytes destinée à être employée en cas de muqueuses sèches
US10603344B2 (en) Plant extract from low-THC cannabis for the treatment of disease
DE69938390T2 (de) Verwendung einer zusammensetzung welche formoterol und budesonide enthält, zur verhinderung oder behandlung eines akuten astmazustandes
EP2164481A2 (fr) Medicament comprenant une combinaison de principes actifs contenant de l'acide pantothenique ou des derives de celui-ci pour traiter les symptomes allergiques
EP2723330B1 (fr) Agent de polythérapie contenant des vasoconstricteurs
EP0125634A1 (fr) Utilisation d'une substance sécrétolytique pour l'obtention d'un agent contre le ronflement et pour combattre le phénomène de ronflement
DE69825279T2 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
EP1526870A1 (fr) Nouvelle combinaison de glucocorticoides et d'inhibiteurs de pde-4 pour traiter des maladies des voies respiratoires, des maladies allergiques, de l'asthme et des maladies pulmonaires chroniques obstructives
DE69725575T2 (de) Verwendung von vitamine e acetat
DE3317530A1 (de) Antischnarchmittel
DE102011103347B4 (de) Nasale pharmazeutische Formulierung
WO2012107356A1 (fr) Composition pharmaceutique aqueuse pour la prévention et/ou la thérapie des irritations allergiques de la muqueuse nasale et son utilisation
DE4433666A1 (de) Mittel zur Behandlung oder Pflege gereizter oder entzündeter Haut enthaltend einen Extrakt aus getrockneten oder frischen Spitzwegerichkraut (Plantago lanceolata. L.) in einer Grundlage, die die Anwendung auf der Haut als Stift, Roller oder Creme ermöglicht
EP3407890B1 (fr) Préparation pharmaceutique et son utilisation pour le traitement de la laryngite virale
DE102020131716A1 (de) Neues Therapiekonzept für die Behandlung von Corona-Infektionen, insbesondere COVID-19-Infektionen
DE202006005924U1 (de) Zusammensetzung zur Behandlung von Rhinitis
DE19746284A1 (de) Kosmetische und pharmazeutische Mittel auf Basis eines Kamillenextraktes
DE2521765A1 (de) Verwendung von uronsaeuren
DE202021105404U1 (de) Neues Therapiekonzept für die Behandlung von Corona-Infektionen, insbesondere COVID-19-Infektionen
WO2022127997A1 (fr) UTILISATION DE β-GALACTOOLIGOSACCHARIDES POUR PRODUIRE UN PRODUIT COSMÉTIQUE ET/OU UNE COMPOSITION PHARMACOLOGIQUEMENT ACTIVE
DE3219994A1 (de) Kombination von pharmaka mit verfluessigender wirkung auf schleimige und schleimig-eiterige sekrete
WO2008022484A2 (fr) Combinaisons d'antagonistes des récepteurs 5-ht3 pour le traitement local d'affections cutanées

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08759102

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 1120080011354

Country of ref document: DE

REF Corresponds to

Ref document number: 112008001135

Country of ref document: DE

Date of ref document: 20100415

Kind code of ref document: P

122 Ep: pct application non-entry in european phase

Ref document number: 08759102

Country of ref document: EP

Kind code of ref document: A1